MIM
PROK icon

MetLife Investment Management’s ProKidney PROK Stock Holding History

MetLife Investment Management’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,918
Closed -$13.4K – 2819
2024
Q4 		$13.4K Sell
7,918
-54,742
-87% -$98.7K ﹤0.01% 2798
2024
Q3 		$120K Buy
62,660
+29,789
+91% +$67.6K ﹤0.01% 2555
2024
Q2 		$80.9K Buy
+32,871
New +$88.2K ﹤0.01% 2680
2023
Q3 		– Sell
-33,094
Closed -$370K – 2960
2023
Q2 		$370K Buy
+33,094
New +$352K ﹤0.01% 1892

Other funds holding PROK

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BU
Brown University Providence, Rhode Island $102M AUM 26.79% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

MetLife Investment Management's PROK Position: Q1 2025 in Review

MetLife Investment Management sold out of ProKidney (PROK) in Q1 2025, closing a stake of 7,918 shares — an estimated $13.4K sold.

MetLife Investment Management first reported a position in PROK in Q2 2023 and held it in 4 quarters. The position peaked at $370K in Q2 2023. 69 funds tracked by Wall St. Rank hold PROK as of Q1 2025.

  • MetLife Investment Management reported no remaining ProKidney position as of Q1 2025 after selling out during the quarter.
  • MetLife Investment Management sold 7,918 ProKidney shares in Q1 2025, an estimated $13.4K.
  • MetLife Investment Management first reported a position in ProKidney in Q2 2023 and held it in 4 quarters.
  • MetLife Investment Management's ProKidney position peaked at $370K in Q2 2023.
  • 69 funds tracked by Wall St. Rank held ProKidney as of Q1 2025.

Based on MetLife Investment Management's 13F filing for Q1 2025, filed 14 May 2025.